Journal article
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
- Abstract:
-
Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare sett...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.8MB, Terms of use)
-
(Preview, Other, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1371/journal.pmed.1004428
Authors
- Publisher:
- Public Library of Science
- Journal:
- PLoS Medicine More from this journal
- Volume:
- 21
- Issue:
- 9
- Article number:
- e1004428
- Publication date:
- 2024-09-12
- Acceptance date:
- 2024-06-14
- DOI:
- EISSN:
-
1549-1676
- ISSN:
-
1549-1277
- Language:
-
English
- Pubs id:
-
2027666
- Local pid:
-
pubs:2027666
- Source identifiers:
-
2257096
- Deposit date:
-
2024-09-13
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2024
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record